Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin

Carcinoma Clinical Trial

Official title:

A Single Arm, Exploratory Clinical Study on the Neoadjuvant Treatment of Neuroendocrine Cervix Carcinoma With Camrelizumab Combined With Etoposide and Cisplatin

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05910177
• Other study ID #: Hhaixin
• Status: Recruiting
• Phase: Phase 2
• Start date: December 28, 2023
• Est. completion date: August 31, 2026

Study information

• Verified date: March 2024
• Source: Fujian Cancer Hospital
• Contact: He Hai Xin
• Phone: 13805056536
• Email: 63804657[@]qq.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a single arm, exploratory clinical study aimed at evaluating the efficacy and safety of karelizumab combined with etoposide and cisplatin in the neoadjuvant treatment of neuroendocrine cervix carcinoma.

Description:

This study is a single arm, exploratory clinical study aimed at evaluating the efficacy and safety of karelizumab combined with etoposide and cisplatin in the neoadjuvant treatment of neuroendocrine cervix carcinoma.Following this, patients achieving complete or partial response will proceed to radical surgery and adjuvant therapy, while those with stable or progressive disease, or considered unsuitable for surgery by gynecological oncologists, will transfer to concurrent chemoradiotherapy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: August 31, 2026
• Est. primary completion date: August 31, 2026
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Age: 18 years = Age = 75 years, female patient. 2. Patients with cervical neuroendocrine carcinoma confirmed by histopathology or cytology (if mixed type carcinoma, the composition of neuroendocrine carcinoma is>60%), whose FIGO stage is stage I-II, and who can be operated according to the gynecological examination of an experienced Chief physician.

3. According to the RECIST 1.1 standard, patients have at least one measurable diameter target lesion (tumor lesion CT scan length = 10mm, lymph node lesion CT scan short diameter = 15mm, scan layer thickness 5mm).

4. ECOG PS 0-1 points. 5. The estimated postoperative survival time is greater than 3 months. 6. The main organs function normally and meet the following standards:

1. The blood routine test must meet the following criteria: (no blood transfusion within 14 days)

1. HB = 100g/L

2. WBC = 3 × 109/L

3. ANC = 1.5 × 109/L

4. PLT = 100 × 109/L

2. Biochemical examination must meet the following standards:

1. BIL<1.5 times upper limit of normal value (ULN)

2. ALT and AST<2.5ULN, GPT = 1.5 × ULN

3. Serum Cr = 1ULN, endogenous creatinine clearance rate>60ml/min (Cockcroft Goult formula).

7. Not participating in other clinical studies before and during treatment.

8. Women of childbearing age must undergo a serum pregnancy study within 7 days before the first medication use, and the results should be negative. Female participants of childbearing age and male participants with partners of childbearing age must agree to contraception within 24 weeks after signing the informed consent form and the last administration of the study medication.

9. The subjects voluntarily joined this study, signed an informed consent form, had good compliance, and cooperated with follow-up.

Exclusion Criteria:

1. Those who have a history of chemotherapy, radiation therapy, targeted drug therapy, or immunotherapy in the past.

2. Patients who have Contraindication to surgical treatment and chemotherapy or whose physical condition and organ function do not allow large abdominal surgery.

3. Distant metastasis.

4. Have any active autoimmune disease or history of autoimmune disease (such as interstitial pneumonia, Uveitis, enteritis, hepatitis, hypophysitis, Vasculitis, Myocarditis, nephritis, Hyperthyroidism, hypothyroidism, including but not limited to these diseases or syndromes); Except for Vitiligo or recovered childhood asthma/allergy patients who do not need any intervention after adulthood; Autoimmune mediated hypothyroidism treated with stable doses of thyroid replacement hormone; Type I diabetes with a stable dose of insulin.

5. Have a history of immune deficiency, including positive Diagnosis of HIV/AIDS, or have other acquired or congenital immune deficiency diseases, or have a history of organ transplantation and allogeneic bone marrow transplantation.

6. Accompanied by severe heart, lung, liver, and kidney diseases; Having neurological or mental illness; Individuals with jaundice or gastrointestinal obstruction and severe infections.

7. Pregnant or lactating women.

8. Suffering from coronary heart disease of grade I or above, arrhythmia (including prolonged QTc interval, female>470 ms), and cardiac dysfunction.

9. Patients with abnormal coagulation function (INR>1.5, APTT>1.5 ULN).

10. The subject has clinical cardiovascular symptoms or diseases that cannot be well controlled, including but not limited to: (1) NYHA grade II or above heart failure, (2) unstable angina pectoris, (3) myocardial infarction within 1 year, (4) clinically significant supraventricular or ventricular arrhythmias that are still poorly controlled without or after clinical intervention.

11. Have a history of Interstitial lung disease (excluding radiation pneumonia without hormone treatment) and non infectious pneumonia.

12. People who have been allergic to any component of Camrelizumab or any component of the study medication in the past.

13. Researchers believe that it is not suitable for inclusion.

Related Conditions & MeSH terms

• Carcinoma
• Cervix Carcinoma

Intervention

Drug:
• Karelizumab combined with etoposide and cisplatin
Karelizumab:200 mg,ivgtt,D1,q3w; Cisplatin:75 mg/m2,ivgtt,D1,q3w; Etoposide:100 mg/m2,ivgtt,D1~3,q3w

Locations

Country	Name	City	State
China	Fujian Cancer Hospital	Fuzhou	Fujian

Sponsors (1)

Lead Sponsor	Collaborator
Fujian Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate	The proportion of participants achieving Complete Response (CR), Partial Response (PR) or Stable Disease (SD) according to RECIST1.1.	6-month
Secondary	Progression-free survival	The period between the onset of treatment and the observation of disease progression or the occurrence of death for any reason.	6-month
Secondary	Disease-free survival period	After radical treatment (complete surgical removal of the tumor), there is no time for the disease to recur.	6-month
Secondary	1 year and 3 year overall survival rates	The proportion of patients who have survived for one and three years after comprehensive treatment.	1 year and 3 year
Secondary	1-year and 3-year progression free survival rates	The probability that the patient's disease will not continue to worsen within one and three years.	1 year and 3 year
Secondary	1-year and 3-year disease control rates	The proportion of patients with reduced or stable tumors within 1 and 3 years.	1 year and 3 year
Secondary	Incidence rate of adverse events	The ratio of the number of cases with adverse events to the total number of cases available for evaluation.	5 years
Secondary	Disease control rate	The proportion of participants achieving Complete Response (CR), Partial Response (PR) or Stable Disease (SD) according to RECIST1.1.	6-month